Abstract
Background Opioids are used to treat patients with chronic pain, but their long-term use is associated with harms. In December 2013, SIGN 136 was published, providing a comprehensive evidence-based guideline for the assessment and management of chronic pain in Scotland
Aims This study aimed to examine the impact of SIGN 136 on opioid prescribing trends and costs across the whole of Scotland.
Methods Opioid prescribing data and average cost per item were obtained from Public Health Scotland. An interrupted time series analysis examined the effects of SIGN 136 publication on the number of items prescribed per 1,000 population per quarter for 29 opioids (or opioid-containing combinations) from 2005 to 2019 inclusive. Exploratory analysis was conducted in NHS Tayside and NHS Fife combined and then up-scaled to all 14 NHS Scotland health boards. A similar approach was also used to assess the effect of SIGN 136 on estimated gross ingredient costs per quarter.
Results At six years post-intervention there was a relative reduction in opioid prescribing of 18.8% (95% CI: 16.0-21.7) across Scotland. There was also a relative reduction of 22.8% (95%: 14.9-30.1) in gross ingredient cost nationally. Opioid prescribing increased significantly pre-intervention across all 14 NHS Scotland health boards (2.19 items per 1000 population per quarter), followed by a non-significant change in level and a significant negative change in trend post-intervention (−2.69 items per 1000 population per quarter). Similar findings were observed locally in NHS Tayside and NHS Fife.
Conclusions The publication of SIGN 136 coincided with a statistically significant reduction in opioid prescribing rates in Scotland and suggests that changes in clinical policy are having a positive effect on prescribing practices in primary care. These prescribing trends appear to be in contrast to the UK as a whole.
Competing Interest Statement
L.A.C. chaired the Guideline Development Group for the Scottish Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which this paper refers, proposed an update due to changing evidence, and contributed to the update of the opioids section. She has been Vice Chair of SIGN since October 2020 and was a member of the Scottish Government group that developed the Quality Prescribing Strategy for Chronic Pain. B.H.S. was a member of the Guideline Development Group for the Scottish Intercollegiate Guideline Network publication, "Management of Chronic Pain" to which this paper refers. He is the Scottish Government's National Lead Clinician for Chronic Pain (since 2014). D.R.M. is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from the Chief Scientist Office (CSO), Health Data Research UK (HDR-UK) and the National Institute of Health Research (NIHR), outside of the submitted work. H.L.H., and N.T. have no conflicts of interest to disclose.
Funding Statement
No external financial support was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used in this study contained no patient or prescriber identifiable information. HIC Standard Operational Procedures have been approved by both the Caldicott Guardian and NHS Tayside Research Ethics Committee and review of individual studies is not required provided that only anonymized data are used and HIC Standard Operational Procedures are followed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary data used in this study are available from the corresponding author, upon reasonable request. Requests for community prescribing data in Scotland can be made to the Health Informatics Centre, University of Dundee and Public Health Scotland.
